Vishal Srivastava | Hematology | Best Researcher Award

Published on by chemical Scientists

Dr. Vishal Srivastava | Hematology | Best Researcher Award

Reserach Associate at Cleveland Clinic in United States.

Dr. Vishal Srivastava 🎓 is a distinguished biomedical researcher specializing in hemophilia A therapy, microbiology, and molecular biology. He earned his Ph.D. in Biological Sciences from CSIR-CDRI/JNU, India, and currently serves as a Postdoctoral Fellow at the Cleveland Clinic 🏥. His groundbreaking work focuses on restoring the secretion and activity of FVIII mutants using FDA-approved small molecules 💊. With a rich research background in genomics, microbiota, and disease pathogenesis, he has received multiple accolades, including the prestigious Judith Graham Pool Postdoctoral Fellowship 🏆. Passionate about translational medicine, Dr. Srivastava is dedicated to advancing innovative treatments for genetic disorders. 🔬✨

Professional Profile
Google Scholar 

🔍 Summary of Suitability:

Dr. Vishal Srivastava is an exceptional candidate for the Best Researcher Award, given his extensive contributions to biomedical science, genomics, and microbiology. With a Ph.D. in Biological Sciences and multiple postdoctoral research positions at prestigious institutions like Cleveland Clinic and The Ohio State University, he has consistently demonstrated excellence in cutting-edge research. His expertise in hemophilia A therapy, small molecule drug discovery, host-microbiota interactions, and infectious diseases makes him a leading scientist in the field.

Education 🎓

✅ Ph.D. in Biological Sciences (2010–2016) – CSIR-Central Drug Research Institute / JNU, India
✅ Master of Science (Biotechnology) (2007–2009) – RGBC, RTM Nagpur University, India
✅ Bachelor of Science (Chemistry, Hons.) (2004–2007) – Banaras Hindu University (BHU), India

Experience 🔬

🔹 Postdoctoral Fellow (2020–Present) – Cleveland Clinic, Genomic Medicine Institute

  • Research on small molecule therapy for hemophilia A mutants 💊

  • Studying FVIII secretion and activity restoration 🧬

🔹 Postdoctoral Researcher (2017–2020) – The Ohio State University

  • Research on antimicrobial therapies and host-pathogen interactions 🦠

  • Investigated microbiota’s role in viral and bacterial infections 🧪

🔹 Senior Research Fellow (2009–2010) – ICAR-National Bureau of Agriculturally Important Microbes

  • Studied microbial genetics for abiotic stress tolerance 🌱

🔹 Ph.D. Researcher (2010–2016) – CSIR-CDRI, India

  • Worked on proteomics and lipidomics of mycobacterial sigma factors 🔍

🔹 Dissertation Research (2008–2009) – RTM Nagpur University

  • Characterized lipase-producing Bacillus species 🧫

 

Professional Development 🚀📖

Dr. Vishal Srivastava has continuously expanded his expertise through diverse research projects, advanced training, and academic contributions. He has honed his skills in proteomics, lipidomics, and molecular biology 🔬, with hands-on experience in genomics and small molecule therapies 💊. As a peer reviewer for reputed journals 📝, he actively evaluates cutting-edge research. His participation in global conferences 🌍, including the Gordon Research Conference, has enriched his scientific outlook. Additionally, his mentorship and teaching experience 👨‍🏫 have shaped aspiring researchers. With multiple prestigious fellowships 🏆, he remains committed to pioneering innovative therapeutic solutions for genetic disorders. 🔍

Research Focus 🔍🤖

Dr. Vishal Srivastava specializes in biomedical research, focusing on hemophilia A therapy, genomics, and microbiology. His work explores small molecule therapies 💊 to restore FVIII secretion in hemophilia patients. He also investigates host-microbiota interactions 🦠, infectious diseases, and antimicrobial resistance. His expertise spans proteomics, lipidomics, and molecular biology to uncover novel therapeutic strategies. Additionally, he has contributed to plant pathology 🌱 and foodborne pathogens research. Through drug discovery 🧪 and genetic disorder studies, he aims to develop cost-effective and accessible treatments, improving global healthcare solutions. His research bridges fundamental science with translational medicine for impactful innovations. 🚀

Awards & Honors 🏆🎖️

✅ Gordon Research Seminar & Conference Travel Grant (2024) ✈️ – Awarded for outstanding research in Hemostasis.

✅ Judith Graham Pool Postdoctoral Research Fellowship (2021–2023) 💰 – Received a $104,000 grant from the National Hemophilia Foundation for FVIII mutant rescue research.

✅ Best Poster Award (3rd Place) 🏅 – Recognized for research on bacterial leaf spot disease control in tomatoes 🍅.

✅ FFH-FIC OSU Seed Grant (2019) 💡 – Co-investigator for research on rotaviral infections and probiotic bacteria ($25,000).

✅ ICMR Senior Research Fellowship (2012–2015) & Junior Research Fellowship (2010–2012) 🔬 – Prestigious Indian medical research fellowships.

✅ CSIR-NET (2008 & 2009) & GATE Life Sciences (2009) 🎓 – Qualified competitive exams for research and teaching.

✅ Biotech Industrial Training Programme (BITP) Fellowship (2009) 🏅 – Selected for specialized biotech training.

✅ Sports Achievements 🏅 – Won 2nd place in Inter-Departmental Kabaddi 🏐 (BHU) & Inter-Divisional Football ⚽ (CDRI).

✅ Language Proficiency 🏆 – Earned a two-year diploma in Italian 🇮🇹.

 

Publication Top Notes:

📌 Protein deficiency reduces efficacy of oral attenuated human rotavirus vaccine in a human infant fecal microbiota transplanted gnotobiotic pig model – A Miyazaki, S Kandasamy, H Michael, SN Langel, FC Paim, J Chepngeno, … 🏆 Vaccine 36 (42), 6270-6281 📅 2018 📖 Cited by: 44

🦠 Characterization of Mycobacterium smegmatis sigF mutant and its regulon: overexpression of SigF antagonist (MSMEG_1803) in M. smegmatis mimics sigF mutant phenotype, loss of … – AK Singh, D Dutta, V Singh, V Srivastava, RK Biswas, BN Singh 🏆 Microbiologyopen 4 (6), 896-916 📅 2015 📖 Cited by: 39

🐔 Identification and characterization of novel small molecule inhibitors to control Mycoplasma gallisepticum infection in chickens – YA Helmy, D Kathayat, M Ghanem, K Jung, G Closs Jr, L Deblais, … 🏆 Veterinary Microbiology 247, 108799 📅 2020 📖 Cited by: 27

💉 Malnutrition decreases antibody secreting cell numbers induced by an oral attenuated human rotavirus vaccine in a human infant fecal microbiota transplanted gnotobiotic pig model – H Michael, SN Langel, A Miyazaki, FC Paim, J Chepngeno, MA Alhamo, … 🏆 Frontiers in Immunology 11, 196 📅 2020 📖 Cited by: 23

🦠 In Vitro and In Vivo Evaluation of Lacticaseibacillus rhamnosus GG and Bifidobacterium lactis Bb12 Against Avian Pathogenic Escherichia coli and Identification … – D Kathayat, G Closs, YA Helmy, L Deblais, V Srivastava, G Rajashekara 🏆 Probiotics and Antimicrobial Proteins, 1-17 📅 2022 📖 Cited by: 21

🧬 hsa-let-7b-5p facilitates Mycobacterium tuberculosis survival in THP-1 human macrophages by Fas downregulation – A Tripathi, V Srivastava, BN Singh 🏆 FEMS Microbiology Letters 365 (7), fny040 📅 2018 📖 Cited by: 20

🧫 Evaluation of novel quorum sensing inhibitors targeting auto-inducer 2 (AI-2) for the control of avian pathogenic Escherichia coli infections in chickens – YA Helmy, D Kathayat, L Deblais, V Srivastava, G Closs Jr, RJ Tokarski, … 🏆 Microbiology Spectrum 10 (3), e00286-22 📅 2022 📖 Cited by: 19

🎯 Conclusion:

Dr. Vishal Srivastava’s groundbreaking discoveries, global impact, and commitment to advancing biomedical research make him a highly deserving candidate for the Best Researcher Award. His work has revolutionized hemophilia A treatment, infectious disease control, and drug discovery, positioning him as a leader in translational medicine. With an outstanding track record, international recognition, and numerous prestigious awards, Dr. Srivastava embodies the excellence and innovation that this award seeks to honor. 🏆🔥